HomeCompareBKUTK vs ABBV

BKUTK vs ABBV: Dividend Comparison 2026

BKUTK yields 3.20% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $58.9K in total portfolio value
10 years
BKUTK
BKUTK
● Live price
3.20%
Share price
$601.00
Annual div
$19.25
5Y div CAGR
25%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$43.4K
Annual income
$5,720.84
Full BKUTK calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — BKUTK vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBKUTKABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BKUTK + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BKUTK pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BKUTK
Annual income on $10K today (after 15% tax)
$272.25/yr
After 10yr DRIP, annual income (after tax)
$4,862.71/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $16,193.29/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BKUTK + ABBV for your $10,000?

BKUTK: 50%ABBV: 50%
100% ABBV50/50100% BKUTK
Portfolio after 10yr
$72.9K
Annual income
$15,246.30/yr
Blended yield
20.92%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

BKUTK
No analyst data
Altman Z
50.7
Piotroski
2/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BKUTK buys
0
ABBV buys
0
No recent congressional trades found for BKUTK or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBKUTKABBV
Forward yield3.20%3.06%
Annual dividend / share$19.25$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR25%40.6%
Portfolio after 10y$43.4K$102.3K
Annual income after 10y$5,720.84$24,771.77
Total dividends collected$20.1K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BKUTK vs ABBV ($10,000, DRIP)

YearBKUTK PortfolioBKUTK Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,100$400.37$11,550$430.00$450.00ABBV
2$12,397$519.19$13,472$627.96$1.1KABBV
3$13,942$677.36$15,906$926.08$2.0KABBV
4$15,808$889.94$19,071$1,382.55$3.3KABBV
5$18,093$1,178.79$23,302$2,095.81$5.2KABBV
6$20,936$1,576.18$29,150$3,237.93$8.2KABBV
7$24,532$2,130.63$37,536$5,121.41$13.0KABBV
8$29,166$2,916.61$50,079$8,338.38$20.9KABBV
9$35,258$4,050.85$69,753$14,065.80$34.5KABBV
10$43,447$5,720.84$102,337$24,771.77$58.9KABBV

BKUTK vs ABBV: Complete Analysis 2026

BKUTKStock

Bank of Utica, together with its subsidiary, provides commercial banking products and services in Utica, New York. The company offers various deposit accounts, including personal checking, business checking, savings, money market, retirement, and health savings accounts; and certificates of deposit. It also provides loans, such as business lines of credit, commercial mortgages, long-term loans, short-term loans, accounts receivable and inventory financing, and federal and NYS government loan programs; and personal loans comprising personal installment loans, vehicle loans, home mortgages, and home equity loans. In addition, the company offers various services that include real-time account balance, funds transfer and management, remote deposit, bill payment, real-time stop payment, check reconciliation, domestic wire transfer, and re-order checks, as well as ACH processing, including payroll; online and mobile banking services; and online bill payment, mobile and direct deposits, and other services. Further, it provides debit and ATM cards, 24/7 telephone banking, and traditional banking services; and invests in securities. Bank of Utica was founded in 1927 and is based in Utica, New York.

Full BKUTK Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this BKUTK vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BKUTK vs SCHDBKUTK vs JEPIBKUTK vs OBKUTK vs KOBKUTK vs MAINBKUTK vs JNJBKUTK vs MRKBKUTK vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.